Prognostic relevance of MYD88 mutations in CLL: the jury is still out

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	BALIAKAS Panagiotis HADZIDIMITRIOU Anastasia AGATHANGELIDIS Andreas ROSSI Davide SUTTON Lesley-Ann KMÍNKOVÁ Jana SCARFO Lydia POSPÍŠILOVÁ Šárka GAIDANO Gianluca STAMATOPOULOS Kostas GHIA Paolo ROSENQUIST Richard
Year of publication	2015
Type	Article in Periodical
Magazine / Source	Blood
MU Faculty or unit	Central European Institute of Technology
Citation
Web	http://www.bloodjournal.org/content/bloodjournal/126/8/1043.full.pdf
Doi	http://dx.doi.org/10.1182/blood-2015-05-648634
Field	Oncology and hematology
Keywords	CHRONIC LYMPHOCYTIC-LEUKEMIA; GENES; SF3B1
Attached files	ZVV_2015_115_1318319_Prognostic_relevance.pdf
Description	Genome surveys have offered a comprehensive view of the genetic landscape of chronic lymphocytic leukemia (CLL), identifying several recurrently mutated genes, including myeloid differentiation primary response 88 (MYD88). The predominant mutation concerns a p.L265P substitution within exon 5,1,2 which leads to constitutive nuclear factor kappaB stimulation, thus conferring a proliferation and survival advantage to the mutant cells.1 MYD88 mutations reach up to 2% to 5% in CLL and are strikingly enriched among patients expressing mutated IGHV genes (M-CLL).
Related projects:	CEITEC - Central European Institute of Technology Molekulární charakterizace B buněčných receptorů a jejich vztah k evoluci genetických změn u chronické lymfocytární leukémie